Ir para conteúdo

Anemia de Células Falciformes/Drepranocitose (Pediatria)

Gestão da Anemia

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (abre uma nova janela)

Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR

Fonte‎: Lancet Haematol. 2023 ;10(4):e261-71.

Indexado‎: PubMed 36870358

DOI‎: 10.1016/S2352-3026(22)00405-7

https://pubmed.ncbi.nlm.nih.gov/36870358/ (abre uma nova janela)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (abre uma nova janela)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Fonte‎: Acta Haematol 1995;94(3):128-34.

Indexado‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (abre uma nova janela)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (abre uma nova janela)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Fonte‎: Haematologica 2006;91(8):1076-83.

Indexado‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (abre uma nova janela)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (abre uma nova janela)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Fonte‎: J Obstet Gynaecol 2007;27(1):82-3.

Indexado‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (abre uma nova janela)